Want to learn more about pediatric drug development? Download an exclusive session from the DIA 2019 Global Annual Meeting discussing practical considerations for the use of master protocols in response to pediatric policy updates:
Industry Perspective: Master Protocols as an Option to Design & Conduct Pediatric Oncology Studies under FDARA, Sec 504
The new requirements in FDARA Section 504 represent a significant paradigm shift in pediatric oncology development. Get an exclusive look at practical considerations for the use of master protocols in small pediatric populations, as presented by Pamela L. Simpkins, MBA, Sr. Director, Strategy Lead, Child Health Innovation Leadership Department (CHILD), Johnson & Johnson.